Kaken Pharmaceutical Company, Ltd.

Tadashi Ohyama

Takahiko Murata

Atsushi Watanabe

Satoru Ikegami

Kimio Hirano

Haruyoshi Ueo

Masahiro Amakawa

There are provided 4-alkynylimidazole derivatives represented by the following general formula (I) or pharmaceutically acceptable salts thereof; the derivatives have a superior EP4 receptor antagonistic action and are useful as pharmaceuticals for the treatment of diseases associated with the EP4 receptor, for example, as anti-inflammatory and/or analgesic drugs for inflammatory diseases and diseases that involve various kinds of pains, and further as pharmaceuticals for the treatment of immune diseases that result from inflammations as evoked by tissue destruction due to the activation of Th1 cells and/or Th17 cells: 

4-alkynyl imidazole derivative and medicine comprising same as active ingredient

Preparations for preventing or treating acute heart failure, chronic heart failure at a phase of acute exacerbation or heart failure at a phase of transition to chronic heart failure, which contain D-alanyl-3-(naphthalen-2-yl)-D-alanyl-L-alanyl-L-tryptophyl-D-phenylalanyl-L-lysinamide and/or salts thereof as an active ingredient.

Preventives or remedies for heart failure

An agent for prevention or treatment of diseases involving degeneration or death of nerve cells, characterized by containing a growth hormone secretion promoting substance as an active ingredient, is provided.

Growing community of inventors

Kyoto, Japan

Tadashi Ohyama